Literature DB >> 19010776

Engineering functional antithrombin exosites in alpha1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa.

Gonzalo Izaguirre1, Alireza R Rezaie, Steven T Olson.   

Abstract

We have previously shown that residues Tyr-253 and Glu-255 in the serpin antithrombin function as exosites to promote the inhibition of factor Xa and factor IXa when the serpin is conformationally activated by heparin. Here we show that functional exosites can be engineered at homologous positions in a P1 Arg variant of the serpin alpha1-proteinase inhibitor (alpha1PI) that does not require heparin for activation. The combined effect of the two exosites increased the association rate constant for the reactions of alpha1PI with factors Xa and IXa 11-14-fold, comparable with their rate-enhancing effects on the reactions of heparin-activated antithrombin with these proteases. The effects of the engineered exosites were specific, alpha1PI inhibitor reactions with trypsin and thrombin being unaffected. Mutation of Arg-150 in factor Xa, which interacts with the exosite residues in heparin-activated antithrombin, abrogated the ability of the engineered exosites in alpha1PI to promote factor Xa inhibition. Binding studies showed that the exosites enhance the Michaelis complex interaction of alpha1PI with S195A factor Xa as they do with the heparin-activated antithrombin interaction. Replacement of the P4-P2 AIP reactive loop residues in the alpha1PI exosite variant with a preferred IEG substrate sequence for factor Xa modestly enhanced the reactivity of the exosite mutant inhibitor with factor Xa by approximately 2-fold but greatly increased the selectivity of alpha1PI for inhibiting factor Xa over thrombin by approximately 1000-fold. Together, these results show that a specific and selective inhibitor of factor Xa can be engineered by incorporating factor Xa exosite and reactive site recognition determinants in a serpin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010776      PMCID: PMC2615528          DOI: 10.1074/jbc.M807340200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

Review 1.  The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature.

Authors:  G A Silverman; P I Bird; R W Carrell; F C Church; P B Coughlin; P G Gettins; J A Irving; D A Lomas; C J Luke; R W Moyer; P A Pemberton; E Remold-O'Donnell; G S Salvesen; J Travis; J C Whisstock
Journal:  J Biol Chem       Date:  2001-07-02       Impact factor: 5.157

Review 2.  Serpin structure, mechanism, and function.

Authors:  Peter G W Gettins
Journal:  Chem Rev       Date:  2002-12       Impact factor: 60.622

3.  Resolution of Michaelis complex, acylation, and conformational change steps in the reactions of the serpin, plasminogen activator inhibitor-1, with tissue plasminogen activator and trypsin.

Authors:  S T Olson; R Swanson; D Day; I Verhamme; J Kvassman; J D Shore
Journal:  Biochemistry       Date:  2001-10-02       Impact factor: 3.162

4.  Mapping of the catalytic groove preferences of factor Xa reveals an inadequate selectivity for its macromolecule substrates.

Authors:  Elsa P Bianchini; Virginie B Louvain; Pierre-Emmanuel Marque; Maria A Juliano; Luiz Juliano; Bernard F Le Bonniec
Journal:  J Biol Chem       Date:  2002-03-29       Impact factor: 5.157

5.  The antithrombin P1 residue is important for target proteinase specificity but not for heparin activation of the serpin. Characterization of P1 antithrombin variants with altered proteinase specificity but normal heparin activation.

Authors:  Y J Chuang; R Swanson; S M Raja; S C Bock; S T Olson
Journal:  Biochemistry       Date:  2001-06-05       Impact factor: 3.162

6.  Role of basic residues of the autolysis loop in the catalytic function of factor Xa.

Authors:  Chandrashekhara Manithody; Likui Yang; Alireza R Rezaie
Journal:  Biochemistry       Date:  2002-05-28       Impact factor: 3.162

7.  Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries.

Authors:  J L Harris; B J Backes; F Leonetti; S Mahrus; J A Ellman; C S Craik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

8.  Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.

Authors:  Trevor P Baglin; Robin W Carrell; Frank C Church; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

9.  Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin.

Authors:  Gonzalo Izaguirre; Richard Swanson; Srikumar M Raja; Alireza R Rezaie; Steven T Olson
Journal:  J Biol Chem       Date:  2007-09-17       Impact factor: 5.157

Review 10.  Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases.

Authors:  Steven T Olson; Yung-Jen Chuang
Journal:  Trends Cardiovasc Med       Date:  2002-11       Impact factor: 6.677

View more
  11 in total

1.  Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).

Authors:  Xiaoping Xu; Margarita Mikhailova; Zhihua Chen; Sanjay Pal; Trista K Robichaud; Eileen M Lafer; Sam Baber; Bjorn Steffensen
Journal:  Matrix Biol       Date:  2011-08-04       Impact factor: 11.583

2.  Identification of serpin determinants of specificity and selectivity for furin inhibition through studies of α1PDX (α1-protease inhibitor Portland)-serpin B8 and furin active-site loop chimeras.

Authors:  Gonzalo Izaguirre; Lixin Qi; Mary Lima; Steven T Olson
Journal:  J Biol Chem       Date:  2013-06-06       Impact factor: 5.157

3.  Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates.

Authors:  Roma Stawikowska; Mare Cudic; Marc Giulianotti; Richard A Houghten; Gregg B Fields; Dmitriy Minond
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

Review 4.  Engineering the serpin α1 -antitrypsin: A diversity of goals and techniques.

Authors:  Benjamin M Scott; William P Sheffield
Journal:  Protein Sci       Date:  2019-12-09       Impact factor: 6.725

Review 5.  Mechanisms of macromolecular protease inhibitors.

Authors:  Christopher J Farady; Charles S Craik
Journal:  Chembiochem       Date:  2010-11-22       Impact factor: 3.164

Review 6.  Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.

Authors:  Steven T Olson; Benjamin Richard; Gonzalo Izaguirre; Sophia Schedin-Weiss; Peter G W Gettins
Journal:  Biochimie       Date:  2010-06-02       Impact factor: 4.079

7.  Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease.

Authors:  Gonzalo Izaguirre; Sonia Aguila; Lixin Qi; Richard Swanson; Ryan Roth; Alireza R Rezaie; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

8.  Kinetic intermediates en route to the final serpin-protease complex: studies of complexes of α1-protease inhibitor with trypsin.

Authors:  Ashoka A Maddur; Richard Swanson; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

9.  Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.

Authors:  Dmitriy Minond; Mare Cudic; Nina Bionda; Marc Giulianotti; Laura Maida; Richard A Houghten; Gregg B Fields
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

10.  Analysis of flavonoid-based pharmacophores that inhibit aggrecanases (ADAMTS-4 and ADAMTS-5) and matrix metalloproteinases through the use of topologically constrained peptide substrates.

Authors:  Mare Cudic; Gayle D Burstein; Gregg B Fields; Janelle Lauer-Fields
Journal:  Chem Biol Drug Des       Date:  2009-09-28       Impact factor: 2.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.